A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

Related Clinical Trial
Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400) Virtual Reality: Influence on Satisfaction, Pain, and Anxiety in Patients Undergoing Colposcopy Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial DNA Methylation Testing for the Screening of Uterine Cervical Lesion Immunohistochemical Staining of p16 for the Screening of Cervical Cancer CASUS: Validation for Detection of Precursor Lesions CASUS: Improved and Quality Assured Collection of First-void Urine Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) Lugol’s Solution in Addition to Acetic Acid During Colposcopy A Phase I Study of E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors Costa Rican Natural History Study of HPV and Cervical Neoplasia Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device Effect of Salpingectomy During Conservative Hysterectomy Feasibility of Delphi Screener for Cervical Cytology Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Gene Therapy Follow up for Subjects Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) – Types in HIV-positive Men Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY Minimally Invasive Benign Hysterectomy HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 – Brazil) Diagnostic Imaging Aid for Management of Cervical Lesions Cervical Cancer Early Endpoints and Determinants Triage Strategies in Cervical Cancer Prevention Genotypification and Predisposing Factors in Human Papilloma Virus Infection Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity Chinese Cancer Prevention Study(CHICAPS) The Development of a “Mother/Child, Screen, Treat and Vaccinate Program” in Manchay and Iquitos, Peru HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings A Trial for Patients With Advanced/Recurrent Cervical Cancer HPV Genotyping by DR. HPV Genotyping in Vitro Diagnostic Device (IVD) Kit in Exfoliated Cells of the Uterine Cervix Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer Self-sampling for Non-attenders to Cervical Cancer Screening HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix Human Papillomavirus Epidemiology in Nigeria Impact of HPV Vaccine On The Prevalence Of HPV In Norway Deciphering Mechanisms Underlying Cancer Immunogenicity Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests Spectroscopic Evaluation of Cervical Neoplasia Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3) Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals’ (GSK Bio) HPV-16/18 Vaccine Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women DNA Methylation Biomarkers for Cervical Cancer Screening Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix Can Text Reminders Improve Uptake of Cervical Screening? Comparing Two Techniques of Haemostasis After Cervical Conization A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening FASTER-Tlalpan Study HPV Integration Testing for Human Papillomavirus-Positive Women Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine Cervical Cytology – Do SMS Reminders Increase Participation in the Cervical Screening Programme? Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection Effectiveness of Cervical Screening in HPV Vaccinated Women Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples Effect of Fee on Attendance in Cervical Cancer Screening Cervix Cytological Screening – Comparison of Tampon Self-Test and the Routine Smear. Study of the Diagnostic Efficacy of “Real Time” Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix LLETZ Under General Versus Local Anesthesia Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs) Trial on Safety and Pharmacokinetics of Intravaginal Curcumin IMproved PRactice Outcomes and Value Excellence in Colposcopy Visual Inspection With Acetic Acid Compared to Lugol’s Iodine in HIV-infected Women Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine Clinical Evaluation of Polarized Light Assisted Colposcopy Indirect Comparison Topotecan Cervical Carcinoma Meta-analysis of Efficacy of Topotecan Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals’ HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study TMTP1-ICG Mapping in Colposcopy-directed Biopsy Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1 Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation The HPV Self-test as a Test of Cure in Madagascar REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins Cold Knife Conization With and Without Lateral Hemostatic Sutures DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2 A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake Improving Cervical Cancer Screening Among HIV-Infected Women in India REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Compass – Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia chemQbiosciences:Manual Liquid Based Cytology A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Music Listening to Reduce Pain and Anxiety During LEEP A Comparison of Immediate Treatment of CIN1 With Cryotherapy and 12 Month Cytology Follow up in HIV Seropositive Women Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia Cervical And Self-Sample In Screening Study Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Factors Associated With Residual Disease In The Central Cone Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Effectiveness of HPV Vaccine in Thai Adult Women Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia Artesunate Vaginal Inserts for the Treatment of CIN2/3 A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) Trial23 – A Method Study on Cervical Screening in Women Offered HPV-vaccination as Girls An Innovative Treatment for Cervical Pre Cancer A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix LLETZ Under Direct Colposcopic Vision The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation LLETZ With Videocolposcopy Versus LLETZ With Binocular Colposcopy Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol Colposcopy and Dynamic Spectral Imaging (DSI) Imiquimod Treatment of High-grade CIN Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Video Colposcopy in Women With Dysplasia Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Imiquimod Treatment of CIN Lesions HPV Integration Testing for Cervical Cancer Screening Hemostatic Procedure After Biopsy of the Cervix HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) Coherence Imaging of the Cervical Epithelium With Scanning a/LCI Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia See and Treat in an Outpatient Setting in Women Above 45 Years With Cervical Dysplasia Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women Smoking Cessation in Women With Gynecological Conditions Recurrence in High-grade Lesions After Conization Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence Management of Cervical Intraepithelial Neoplasia Grade 2 Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) An Innovative Treatment for Cervical Precancer (UH3) Evaluating Materials to Educate Patients About Cervical Dysplasia A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia Performance, Safety, and Efficacy of a New Cryotherapy Device for Cervical Dysplasia [Part II] Music and Colposcopy in Women With Cervical Dysplasia. Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 Focal Ablation of Cervical Precancer Digital Imaging Aid for Assessment of Cervical Dysplasia Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2) Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia Can Alternative Treatment Have an Impact on Cervical Dysplasia? Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure

Brief Title

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

Official Title

A PHASE II SINGLE-ARM INTERVENTION TRIAL OF NELFINAVIR IN PATIENTS WITH GRADE 2/3 or 3 CERVICAL INTRAEPITHELIAL NEOPLASIA

Brief Summary

      Preliminary data showed that Nelfinavir has selective apoptotic effects on HPV+ cervical
      tumor cell lines. Furthermore, in a Phase I clinical trial, the combination of NFV and
      chemoradiotherapy showed acceptable toxicity and promising activity in patients with
      pancreatic cancer. Therefore, for the proposed research, the principal investigator will use
      a single-arm Phase II intervention trial study design with focus on the efficacy of NFV to
      induce complete or partial remission of CIN 2/3 or CIN 3 as well as biomarker evaluation.
    

Detailed Description

      2.0 BACKGROUND AND RATIONALE 2.1 Cervical Cancer Etiology and Targets for Intervention
      Cervical cancer is one of the most common causes of cancer-related deaths in women worldwide.
      Implementation of widespread screening has created drastic improvements in the incidence of
      cervical cancer as well as significant decreases in mortality over the last 30 years. It is
      estimated that in 2011, there will be 12,710 women in the US diagnosed with cervical cancer
      and ultimately 4,290 women will die from the disease. Cervical cancer is unique in that there
      exists a well-defined pre-malignant phase, referred to as cervical dysplasia, which can be
      suspected on cytological examination (pap smear) of exfoliated cervical cells and confirmed
      on histological examination of cervical biopsy material. The pre-cancerous changes represent
      a spectrum of histological abnormalities or cervical intraepithelial neoplasia (CIN) ranging
      from CIN 1 (mild dysplasia) to CIN2 (moderate dysplasia) to CIN3 (severe dysplasia/ carcinoma
      in situ). The timeline of progression for CIN 3 to invasive cancer in untreated women
      averages between 8.1 and 12.6 years.The surgical treatment of cervical pre-cancerous is
      therapeutically efficacious. However, it is an invasive procedure which has been associated
      with fertility and obstetrical complications in reproductive aged women. An attractive
      alternative to an excisional or ablative procedure would be to utilize an agent which could
      be applied topically or taken by mouth to foster regression of cervical dysplasia. The use of
      natural, synthetic, or biologic chemical agents to reverse, suppress, or prevent carcinogenic
      progression is called chemoprevention.

      A prerequisite for cervical cancer is persistent infection by a high-risk human
      papillomavirus allowing viral gene products sufficient time with which to induce
      carcinogenesis through a generally well understood natural history. Cancer-associated HPV
      types encode three oncogenes, E5, E6 and E7, and the E6 and E7 proteins have a significant
      role in malignant transformation. E6 and E7 stimulate cell proliferation by interfering with
      the function of regulatory proteins in cells, including the tumor suppressors p53 and pRB.
      Co-expression of both E6 and E7 leads to indefinite proliferation and immortalization of
      keratinocytes and induces premalignant neoplasms. HPV-E5, a transmembrane protein, can
      activate PI3K-Akt signalling. The up-regulation of PI3K-Akt survival signaling protects
      HPV-16 E5-expressing cells from apoptosis induced by ultraviolet irradiation. The major
      transforming capability of HPV is dependent on E6 and E7. However, E5 is necessary for full
      activation of E7, and the induction of PI3K-Akt-dependent apoptotic inhibition by E5
      contributes to E7-mediated oncogenesis.

      The work done to evaluate PI3K activity as a potential marker of CIN progression further
      supports the idea that this pathway is also up-regulated in pre-cancerous lesions. The
      catalytic subunit alpha of PI3K is expressed in non-invasive cervical lesions and has shown
      potential as a carcinogenesis-related marker for early intraepithelial lesion of the uterine
      cervix in cytology samples. Among other potential markers, PIK3CA showed a superior
      specificity to distinguish CIN3 from other groups. Yao et al 2008 showed that positive rates
      of PI3K and Akt were significantly lower in normal cervical epithelium and cervical
      intraepithelial neoplasia than in cervical carcinoma (0.0% and 42.9% vs. 69.7%, P<0.01; 10.0%
      and 52.4% vs. 75.0%,P<0.01). Specifically, PI3K/Akt activation increased with grade of
      dysplasia with invasive carcinoma having the highest activity. They also showed that
      expression of PI3K protein positively correlated to the expression of Akt protein(r=0.425,
      P<0.01).

      2.2 Nelfinavir (NFV) Background Nelfinavir (NFV) induces cell cycle arrest, endoplasmic
      reticulum stress, autophagy, and apoptosis is cancer cells. As a protease inhibitor used in
      patients with HIV, NFV predominately targets proteases 1 and 2, but it is also known that
      part of the efficacy is due to selective inhibition of the proteosome. The pathogenecity of
      high risk HPV is dependent on expression of viral E6 proteins which inappropriately activate
      the 26S proteosome to degrade p53 and other cellular proteins that are detrimental to viral
      replication; specific HIV protease inhibitors can block the ability of HPV16 E6 to degrade
      p53 and selectively kill E6-dependent cervical carcinoma cells. Furthermore, HIV protease
      inhibitors have been shown to inhibit the PI3K/Akt signaling pathway with NFV being the most
      potent. NFV's mechanism of action involves decreasing Akt phosphorylation. In addition, at
      concentrations (micromolar) achievable in the serum of patients taking usual dosing of the
      drug (1250mg PO BID), Akt phosphorylation is inhibited. At our institution, we have shown
      that HPV-infected cervical cancer cells lines treated with NFV underwent apoptosis and
      decreased cell proliferation in a dose dependent manner. Furthermore, we have shown through a
      recent retrospective study that HIV-infected women with cervical dysplasia who were treated
      with protease inhibitors (PI), including NFV were more likely to regress than those not on a
      PI-containing regimen.

      Because PI3K/Akt is up-regulated in CIN2/3 and NFV has been shown to inhibit this pathway in
      HPV-infected cervical cancer cell lines, we aim to further evaluate the effectiveness of NFV
      as an intervention for CIN2/3 and correlate these findings with phospho-Akt levels in
      cervical tissue. Several intervention trials have been conducted in women with CIN using
      retinoids, ß-carotene, difluoromethylornithine, and indole-3- carbinol and over 300 women
      with CIN 3 were followed in these trials for one to 15 months while none of them developed
      invasive cervical cancer. Therefore, this proposed intervention trial of 24 weeks (6 months)
      duration should allow a safe evaluation of NFV as a potential agent for a future randomized
      Phase III trial.

      Development of a new drug for cancer treatment is expensive and time consuming. Repositioning
      of a drug which is already FDA approved for another indication allows for more rapid
      evaluation and potential implementation of a novel cancer therapy. NFV has been identified to
      have anti-cancer effects in vitro, and compared to other protease inhibitors it is more
      potent in causing cell death. NFV has over 10 years of safety and pharmacokinetic data in
      HIV-infected individuals. Standard dosing for the treatment of HIV is 1,250 mg PO BID, and
      this dose has demonstrated plasma concentrations in vivo which correlate with necessary
      concentrations of successful in vitro studies. Furthermore, evaluation of the standard dose
      offers the availability of commercially produced tablets, the known and acceptable side
      effect profile, and the ease of twice daily dosing. For these reasons NFV is an excellent
      candidate for repositioning as an intervention for cervical dysplasia, which can be quickly
      evaluated in this phase II clinical trial.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

1.1 Efficacy of Nelfinavir (NFV) to induce complete remission (or partial regression to CIN 1) of CIN 2/3 or CIN 3 as evaluated in the post-treatment excisional biopsy.

Secondary Outcome

 targeted mechanism of NFV in histological response

Condition

Cervical Dysplasia

Intervention

Nelfinavir

Study Arms / Comparison Groups

 Nelfinavir
Description:  This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

0

Start Date

November 7, 2018

Completion Date

December 2022

Primary Completion Date

December 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have a Cytology report with a High Grade Squamous Intra Epithelial
             Lesion "HSIL" or have histologically proven CIN 2/3 or CIN 3 diagnosed by cervical
             biopsy between 2 and 8 weeks prior to enrollment. For a patient to be eligible, the
             Cytology report must state High Grade Squamous Intra Epithelial Lesion "HSIL" or the
             pathology report must clearly state "CIN 2/3" or "CIN 3" or must state
             "moderate-severe dysplasia", "moderate severe dyskaryosis," "severe dysplasia," or
             "severe dyskaryosis." Patients with a diagnosis of CIN 2 alone or moderate dysplasia
             or dyskaryosis alone are not eligible for this study.

          -  Patients must be at least 18 years of age.

          -  Patients must have a satisfactory (readable, good quality) colposcopic evaluation at
             least 14 days after diagnostic biopsy.

          -  Patients must have colposcopically visible cervical lesion at entry consistent with
             biopsy.

          -  Patients must have a negative urine pregnancy test within 14 days of starting the NFV.
             Women of childbearing potential must practice an acceptable form of contraception
             (e.g. intrauterine device, contraceptive pills, diaphragm, condoms).

          -  Patients must have a GOG Performance Status of 0, 1, or 2.

          -  Patients must be good candidates for delayed treatment of their CIN, i.e. they must be
             reliable to return for follow-up and provide a combination of at least three phone
             numbers or addresses for contact.

          -  Patients must have adequate*:

          -  CBC/Platelets: Hemoglobin (HgB) greater than 10.0g/dl; white blood cell (WBC) count
             greater than 3000/mcl; Platelet count greater than 125,000/mcl.

          -  Renal function: Creatinine less than or equal to 1.5 x Upper Limit Normal (ULN).

          -  Hepatic function: Total bilirubin less than or equal to 1.5 x ULN excluding Gilbert's
             disease; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.0 x
             ULN.

          -  Glycemic control: fasting glucose < 126; random glucose <200; hemoglobin A1C ≤ 7.0%

             *These lab results must be evaluated prior to patient enrollment.

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information.

          -  Patients must have a negative HIV test within 14 days of starting the NFV.

          -  Patients with allergies or known sensitivity to Nelfinavir will be excluded or
             withdrawn after treatment, if deemed a safety concern by the principal Investigator.

        Exclusion Criteria:

        Ineligible Patients

          -  Patients who are pregnant or breast-feeding.

          -  Patients with cytologic or biopsy evidence of endocervical dysplasia or invasive
             cancer.

          -  Patients with undiagnosed abnormal vaginal bleeding.

          -  Patients with a known immunocompromised condition or a positive HIV test. Patients
             with a prior history of cervical cancer.

          -  Patients with a chronic or acute renal, or hepatic disorder, a significant bleeding
             disorder, or any other condition which in the Investigator's opinion might preclude
             study participation for the duration of the trial.

          -  Patients taking concurrent medication that is metabolized by the CYP3A4 isoenzyme.

          -  Patients taking the following concurrent medications: astemizole, cisapride,
             salmeterol, alfuzosin, terfinadine, amiodarone, midazolam, quinadine, ergot
             derivatives, pimozide, rifampin, triazolam, warfarin, azithromycin, carbamezpine,
             cyclosporine, didanosine, fluticasone propionate, phenobarbital, phenytoin, trazadone,
             sirolimus, tacrolimus , and St. John's wart.

          -  Patients who are unwilling, or unable, to practice an acceptable form of contraception
             (e.g. intrauterine device, contraceptive pills, diaphragm, condoms). For those women
             who choose to use oral contraceptive pills, they will be encouraged to use a second
             form of contraception, such as condoms, because of the potential for altered serum
             levels of oral contraceptives.

          -  Patients with uncontrolled diabetes; as defined by hemoglobin A1C ≥ 7.1%
      

Gender

Female

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Joseph A Lucci, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01925378

Organization ID

20110917-01


Responsible Party

Principal Investigator

Study Sponsor

The University of Texas Health Science Center, Houston


Study Sponsor

Joseph A Lucci, MD, Principal Investigator, The University of Texas Health Science Center, Houston


Verification Date

November 2020